booster influenza vaccine shows promising progress.
Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that all participants have completed their final visit in the Phase 2a clinical booster trial (NCT06582277) evaluating OVX836, Osivax’ broad-spectrum influenza A vaccine candidate. Osivax expects to announce final results from the booster trial in H2 2025.
The The single-center, randomized, double-blind, Phase 2a clinical trial is being conducted at the Center for Vaccinology (CEVAC), Ghent University Hospital, in Belgium. The trial is evaluating the immunogenicity and safety of one single dose of OVX836 administered intramuscularly (IM) at either 180μg or 480μg. The study includes 117 healthy adults aged 20-64 who previously participated in Osivax’ Phase 2 trials (NCT04192500 or NCT05060887), conducted 3 and 5 years ago, respectively, and who received either OVX836 (180μg, 300μg or 480μg), Influvac® Tetra, or placebo. Participants who had previously received a placebo or Influvac® Tetra now serve as controls and have received the highest dose of OVX836 (480 µg) as a primary vaccination.